US20130171620A1 - Viral variants and methods for detecting same - Google Patents
Viral variants and methods for detecting same Download PDFInfo
- Publication number
- US20130171620A1 US20130171620A1 US13/547,392 US201213547392A US2013171620A1 US 20130171620 A1 US20130171620 A1 US 20130171620A1 US 201213547392 A US201213547392 A US 201213547392A US 2013171620 A1 US2013171620 A1 US 2013171620A1
- Authority
- US
- United States
- Prior art keywords
- domain
- hbv
- amino acid
- mutation
- polymerase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims description 34
- 230000003612 virological effect Effects 0.000 title abstract description 32
- 238000003556 assay Methods 0.000 claims abstract description 19
- 230000002829 reductive effect Effects 0.000 claims abstract description 17
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 15
- 230000035772 mutation Effects 0.000 claims description 88
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 58
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 57
- 108020004414 DNA Proteins 0.000 claims description 37
- 125000003729 nucleotide group Chemical group 0.000 claims description 35
- 239000002773 nucleotide Substances 0.000 claims description 34
- 150000001413 amino acids Chemical class 0.000 claims description 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 29
- 229940127073 nucleoside analogue Drugs 0.000 claims description 28
- 238000006467 substitution reaction Methods 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 108700024845 Hepatitis B virus P Proteins 0.000 claims description 19
- 230000035945 sensitivity Effects 0.000 claims description 19
- 125000000539 amino acid group Chemical group 0.000 claims description 17
- 238000012217 deletion Methods 0.000 claims description 14
- 230000037430 deletion Effects 0.000 claims description 14
- 230000003247 decreasing effect Effects 0.000 claims description 12
- 230000006229 amino acid addition Effects 0.000 claims description 10
- 238000012216 screening Methods 0.000 claims description 10
- 238000009396 hybridization Methods 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 8
- 238000012163 sequencing technique Methods 0.000 claims description 8
- 101100020228 Homo sapiens KLHL31 gene Proteins 0.000 claims description 6
- 102100033584 Kelch-like protein 31 Human genes 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 108091035707 Consensus sequence Proteins 0.000 claims description 3
- 108020004999 messenger RNA Proteins 0.000 claims description 3
- 230000000840 anti-viral effect Effects 0.000 abstract description 19
- 230000001900 immune effect Effects 0.000 abstract description 13
- 208000002672 hepatitis B Diseases 0.000 abstract description 7
- 230000001747 exhibiting effect Effects 0.000 abstract description 6
- 230000036961 partial effect Effects 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 238000012544 monitoring process Methods 0.000 abstract description 2
- 239000002777 nucleoside Substances 0.000 abstract description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract description 2
- 229940124597 therapeutic agent Drugs 0.000 abstract description 2
- 241000700721 Hepatitis B virus Species 0.000 description 118
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 46
- 239000000427 antigen Substances 0.000 description 40
- 102000036639 antigens Human genes 0.000 description 40
- 108091007433 antigens Proteins 0.000 description 40
- 235000001014 amino acid Nutrition 0.000 description 33
- 238000011282 treatment Methods 0.000 description 33
- 229940024606 amino acid Drugs 0.000 description 30
- 229960004396 famciclovir Drugs 0.000 description 28
- 238000002560 therapeutic procedure Methods 0.000 description 15
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 14
- 238000003752 polymerase chain reaction Methods 0.000 description 14
- 108700026244 Open Reading Frames Proteins 0.000 description 12
- 241000700605 Viruses Species 0.000 description 11
- KGSIOVLUJYQLKR-UHFFFAOYSA-N [[4-(2-amino-6-oxo-3h-purin-9-yl)-2-(hydroxymethyl)butoxy]-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C=N2 KGSIOVLUJYQLKR-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 7
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 241000700584 Simplexvirus Species 0.000 description 6
- 102220028430 rs386352332 Human genes 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 5
- 108010082126 Alanine transaminase Proteins 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 5
- 229960001627 lamivudine Drugs 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 229960001179 penciclovir Drugs 0.000 description 4
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- 102200107877 rs140122268 Human genes 0.000 description 4
- 102200002611 rs431905508 Human genes 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 101150003160 X gene Proteins 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 229960002963 ganciclovir Drugs 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 102220512213 Adenine DNA glycosylase_L526M_mutation Human genes 0.000 description 2
- 241000272525 Anas platyrhynchos Species 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- GXDLGHLJTHMDII-WISUUJSJSA-N Thr-Ser Chemical group C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(O)=O GXDLGHLJTHMDII-WISUUJSJSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229960005102 foscarnet Drugs 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000006054 immunological memory Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 102220321276 rs1038089558 Human genes 0.000 description 2
- 102220075491 rs145238683 Human genes 0.000 description 2
- 102220023144 rs387907494 Human genes 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241001640117 Callaeum Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 241000243321 Cnidaria Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 206010019754 Hepatitis cholestatic Diseases 0.000 description 1
- 208000037262 Hepatitis delta Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 125000000899 L-alpha-glutamyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- YSGAPESOXHFTQY-IHRRRGAJSA-N Tyr-Met-Asp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N YSGAPESOXHFTQY-IHRRRGAJSA-N 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 231100000836 acute liver failure Toxicity 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 231100000838 cholestatic hepatitis Toxicity 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000029570 hepatitis D virus infection Diseases 0.000 description 1
- 230000008935 histological improvement Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- ADKOXSOCTOWDOP-UHFFFAOYSA-L magnesium;aluminum;dihydroxide;trihydrate Chemical compound O.O.O.[OH-].[OH-].[Mg+2].[Al] ADKOXSOCTOWDOP-UHFFFAOYSA-L 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000005257 nucleotidylation Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 102220230609 rs1064796737 Human genes 0.000 description 1
- 102220168283 rs140097244 Human genes 0.000 description 1
- 102220236071 rs143491365 Human genes 0.000 description 1
- 102220108973 rs28763904 Human genes 0.000 description 1
- 102220093943 rs876658576 Human genes 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B variants exhibiting complete or partial resistance to nucleoside analogues and/or reduced interactivity with antibodies to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic regimes.
- HBV Hepatitis B Virus
- the HBV genome is of a complex nature having a partially double stranded DNA structure with overlapping open reading frames encoding surface, core, polymerase and X genes.
- the complex nature of the HBV genome is represented in FIG. 1 .
- nucleoside analogues could act as effective anti-viral agents.
- nucleoside analogues currently being tested are penciclovir and its oral form famciclovir (2, 3, 4, 5) and lamivudine (6,7). There is potential for such agents to be used in the treatment of chronic HBV infection.
- Peniciclovir has been recently shown to have potent inhibitory activity against duck HBV DNA synthesis in vitro and has been shown to inhibit HBV DNA polymerase-reverse transcriptase activity in vitro (8,9). Similarly, oral famiciclovir has been demonstrated to inhibit intra-hepatic replication of duck HBV virus in vivo (10). In man, famciclovir has been shown to reduce HBV DNA replication in a patient with severe hepatitis B following orthotopic liver transplantation (OLT) (11).
- OHT orthotopic liver transplantation
- nucleoside analogue antiviral therapy was used to control severe post-OLT recurrence of HBV infection (12).
- Long term therapy is mandatory where patients are immunosuppressed and the rate of HBV replication is very high.
- any long term chemotherapy of infectious agents there is a potential for development of resistance or reduced sensitivity to the therapeutic agents employed.
- the inventors have identified variants of HBV with mutations in the HBV DNA polymerase gene which to varying extents reduce the sensitivity of HBV to nucleoside analogues.
- the identification of these HBV variants is important for the development of assays to monitor nucleoside analogue therapeutic regimes and to screen for agents which can mask the effects of the mutation.
- the HBV genome comprises a series of overlapping open reading frames, a nucleotide mutation in one open reading frame can affect translation products in another open reading frame.
- the inventors have observed mutations which reduce the interactivity of immunological reagents, such as antibodies and immune cells, to viral surface components. Such viral variants are referred to herein as “escape mutants” since they potentially escape existing immunological memory.
- one aspect of the present invention is directed to a variant of an isolated DNA virus which replicates via an RNA intermediate wherein said variant comprises a nucleotide mutation in a gene encoding a DNA polymerase resulting in at least one amino acid addition, substitution and/or deletion to said DNA polymerase.
- Another aspect of the present invention provides a variant of an isolated DNA virus which replicates via an RNA intermediate wherein said variant comprises a nucleotide mutation in a gene encoding a viral surface component resulting in at least one amino acid addition, substitution and/or deletion in said viral surface component.
- Still a further aspect of the present invention is directed to a variant of an isolated DNA virus which replicates via an RNA intermediate at least wherein said variant comprises a nucleotide mutation in an overlapping portion of at least two open reading frames resulting in an amino acid addition, substitution and/or deletion to translation products of said open reading frames.
- the DNA virus is a hepatitis virus or a related virus and is most preferably HBV.
- a “related virus” in accordance with the present invention is one related at the genetic, immunological, epidemiological and/or biochemical levels.
- the mutation in the DNA polymerase results in decreased sensitivity of the HBV to a nucleoside analogue.
- the mutation in the viral surface component reduces the interactivity of immunological reagents such as antibodies and immune cells to the viral surface component.
- the viral surface component is a viral surface antigen.
- the reduction in the interactivity of immunological reagents to a viral surface component generally includes the absence of immunological memory to recognise or substantially recognise the viral surface component.
- a viral variant may, in accordance with a preferred aspect of the present invention, carry mutation only in the DNA polymerase or the surface antigen or may carry a mutation in both molecules.
- the term “mutation” is to be read in its broadest context and includes a silent mutation not substantially affecting the normal function of the DNA polymerase or surface antigen or may be an active mutation having the effect of inducing nucleoside analogue resistance or an escape mutant phenotype. Where multiple mutations occur in accordance with the present invention or where multiple phenotypes result from a single mutation, at least one mutation must be active or the virus must exhibit at least one altered phenotype such as nucleoside analogue resistance or reduced immunological interactivity to the surface antigen.
- Regions of the HBV polymerase show amino acid similarity with other RNA-dependent DNA polymerases and RNA-dependent polymerases (13). In this specification, reference is made to the conserved regions defined by Poch et al (13) as domains B and C.
- the mutation results in an altered amino acid sequence in the B domain and/or C domain or regions proximal thereto of the HBV DNA polymerase.
- the present invention does not extend to a mutation alone in the YMDD motif of the C domain of the HBV DNA polymerase although such a mutation is contemplated by the present invention if it occurs in combination with one or more mutations in another location.
- the mutation in the viral surface component is preferably in one or more amino acid residues within the major hydrophilic regions of the protein, in particular within the amino acid sequence 118-169 of the HBV viral surface antigen and also the regions from amino acids sequence 169 to 207 which are on the external surface of the protein.
- an HBV variant comprising a mutation in the nucleotide sequence encoding a DNA polymerase resulting in an amino acid addition, substitution and/or deletion in said DNA polymerase in its B domain and/or C domain or in a region proximal thereto, provided said mutation is not in the YMDD motif of the C domain alone, and wherein said variant exhibits decreased sensitivity to a nucleoside analogue.
- HBV variant comprising a mutation in the nucleotide sequence encoding a viral surface component resulting in an amino acid addition, substitution and/or deletion in said viral surface component in a region corresponding to the B domain and/or C domain of HBV DNA polymerase or a region proximal to the B domain and/or C domain of HBV DNA polymerase and wherein said variant exhibits decreased interactivity of immunological reagents to said viral surface component.
- Yet another preferred aspect of the present invention relates to an HBV variant comprising a mutation in the nucleotide sequence encoding a viral surface component resulting in an amino acid addition, substitution and/or addition in said viral surface component in a region defined by amino acids 118 to 169 and also 169 to 207 of the HBV surface antigen or functionally equivalent region wherein said variant exhibits decreased interactivity of immunological reagents to said viral surface component.
- Still yet another aspect of the present invention is directed to an HBV variant comprising a mutation in an overlapping open reading frame in its genome wherein said mutation is in the B and/or C domain of DNA polymerase provided that it is not in the YMDD (SEQ ID NO 30) motif of the C domain alone; and in the overlapping region corresponding to amino acids 118 to 169 and also 169 to 207 or equivalent of HBV surface antigen and wherein said variant exhibits decreased sensitivity to a nucleotide analogue and exhibits decreased interactivity to immunological reagents specific to HBV surface antigens.
- the viral variant exhibiting reduced interactivity to immunological reagents is an escape mutant since antibodies or other immunological response to HBV from a prior exposure to the virus or following vaccination are no longer effective in targeting a viral surface component since the mutation has altered a B- and/or T-cell epitope on the surface antigen.
- nucleoside analogues contemplated by the present invention include penciclovir and its oral form famciclovir as well as lamivudine (3TC).
- Different variants may be resistant to different nucleoside analogues.
- a variant in the B domain of HBV DNA polymerase may be resistant to famciclovir whereas a variant in the C domain may be resistant to 3TC.
- the B domain is considered to comprise amino acid residues 505 to 529 of HBV DNA polymerase. This sequence is represented as follows (SEQ ID NO 24):
- Reference to the B domain includes reference to proximal regions which includes up to about 20 amino acids on either side of the domain.
- the mutation is in one or more of the following amino acids (SEQ ID NO 25):
- the C domain comprises amino acids 546 to 556 as follows (SEQ ID NO 26):
- residue number 530 This includes the YMDD domain in which the methione residue is considered residue 550 (formally regarded as residue number 530).
- residue numbering in this specification has been adjusted according to the new numbering system where the methione of YMDD is 550.
- Reference to the C domain includes proximal regions of up to 20 amino acids either side of the domain.
- Aresistance ⁇ is used in its most general sense and includes total resistance or partial resistance or decreased sensitivity to a nucleoside analogue.
- the variants are in isolated form such that they have undergone at least one purification step away from naturally occurring body fluid.
- the variants may be maintained in isolated body fluid or may be in DNA form.
- the present invention also contemplates infectious molecular clones comprising the genome or parts thereof from a variant HBV.
- Preferred mutations in the HBV DNA polymerase include one or more of Gly498Glu, Arg/Trp499Lys, Thr530Ser, Ile509Val, Phe512Leu, Val519Leu, Pro523Leu, Leu526Met, Ile533Leu, Met550Val/Ile and/or Ser559Thr.
- Preferred mutations in the HBV surface antigen include one or more of Asp144Glu and/or Gly145Arg. These correspond to positions 498 and 499 of DNA polymerase, respectively. More preferably, the variants contain two or more of the above-mentioned mutations.
- One particular mutant HBV has the nucleotide sequence set forth in SEQ ID NO:17 and exhibits a multiphenotypic mutation rendering the DNA polymerase resistant to nucleoside analogues and an altered surface antigen such that it has reduced interactivity with antibodies to HBV surface antigen.
- the mutation is G498E in the DNA polymerase open reading frame as D144E and G145R in the surface antigen. This results from a double mutation in nucleotide numbers 226 and 227 of SEQ ID NO:17 to G and A.
- the polymerase protein of HBV is also similar to the DNA polymerase of Herpes Simplex Virus (HSV) (see FIG. 3 for alignment).
- a mutation (Gly841Cys) in the HSV polymerase gene was selected for in the presence of famciclovir (15). This mutation occurs in the same position as the G498E mutation of the HBV polymerase.
- the present invention extends to the nucleotide sequence set forth in SEQ ID NO:17 as well as a nucleotide sequence having at least 60% similarity thereto and which carries a double mutation in the amino acid sequence of DNA polymerase and the HBV surface antigen. Accordingly, the present invention is directed to an HBV having the nucleotide sequence as set forth in SEQ ID NO:17 or a derivative thereof having a single or multiple nucleotide addition, substitution and/or deletion thereto such as a nucleotide sequence having at least 60% similarity to SEQ ID NO:17.
- a derivative includes parts, fragments, portions and homologues of SEQ ID NO:17.
- This aspect of the present invention also extends to a nucleotide sequence capable of hybridizing under low stringency conditions at 421C to SEQ ID NO:17.
- Reference herein to a low stringency at 42 EC includes and encompasses from at least about 1% v/v to at least about 15% v/v formamide and from at least about 1M to at least about 2M salt for hybridisation, and at least about 1M to at least about 2M salt for washing conditions.
- Alternative stringency conditions may be applied where necessary, such as medium stringency, which includes and encompasses from at least about 16% v/v to at least about 30% v/v formamide and from at least about 0.5M to at least about 0.9M salt for hybridisation, and at least about 0.5M to at least about 0.9M salt for washing conditions, or high stringency, which includes and encompasses from at least about 31% v/v to at least about 50% v/v formamide and from at least about 0.01M to at least about 0.15M salt for hybridisation, and at least about 0.01M to at least about 0.15M salt for washing conditions.
- medium stringency which includes and encompasses from at least about 16% v/v to at least about 30% v/v formamide and from at least about 0.5M to at least about 0.9M salt for hybridisation, and at least about 0.5M to at least about 0.9M salt for washing conditions
- high stringency which includes and encompasses from at least about 31% v/v to at least about 50% v/v form
- another aspect of the present invention contemplates a variant HBV exhibiting reduced sensitivity to a nucleoside analogue and reduced interactivity to an antibody to wild-type HBV surface antigen, said HBV variant characterised by one or more of the following characteristics:
- a variant HBV comprising a nucleotide sequence which encodes a DNA polymerase having the amino acid sequence (SEQ ID NO:27 and SEQ ID NO:28):
- X 1 is S or A
- nucleoside analogue such as famciclovir (penciclovir) and/or lamivudine (3TC).
- Another embodiment of the present invention is directed to a variant HBV comprising a nucleotide sequence which encodes a surface antigen having at least one amino acid substitution, addition and/or deletion to amino acid residue numbers 118 to 169 and also 169 to 207 of said surface antigen which corresponds to a DNA polymerase having the amino acid sequence (SEQ ID NO:42 and SEQ ID NO:43):
- X 16 is Q or K
- said variant exhibits reduced interactivity with immunological reagents, such as an antibody, to said surface antigen.
- Examples of preferred variants comprise the amino acid sequences shown in FIG. 4 .
- An example of a particularly preferred mutant is shown in FIG. 5 (SEQ ID NO:17).
- the identification of the variants of the present invention permits the generation of a range of assays to detect such variants.
- the detection of such variants may be important in identifying resistant variants to determine the appropriate form of chemotherapy and/or to monitor vaccination protocols.
- another aspect of the present invention contemplates a method for determining the potential for an HBV to exhibit reduced sensitivity to a nucleoside analogue, said method comprising isolating DNA or corresponding mRNA from said HBV and screening for a mutation in the nucleotide sequence encoding HBV DNA polymerase resulting in at least one amino acid substitution, deletion and/or addition in the B domain or C domain or a region proximal thereto of said DNA polymerase wherein the presence of such a mutation is an indication of the likelihood of resistance to said nucleoside analogue.
- a further aspect of the present invention provides a method for determining the potential for an HBV to exhibit reduced interactivity to antibody to HBV surface antigen, said method comprising isolating DNA or corresponding mRNA from said HBV and screening for a mutation in the nucleotide sequence encoding HBV surface antigen resulting in at least one amino acid substitution, deletion and/or addition in amino acids 118 to 169 and/or 169 to 207 of said surface antigen or a region proximal thereto of said surface antigen wherein the presence of such a mutation is an indication of the likelihood of reducing interactivity of said antibodies to said mutated surface antigen.
- the assay determines a mutation resulting in a Glu/Val519Leu substitution and/or a Leu526Met substitution and/or a Pro523Leu substitution and/or a S559T substitution, and/or Gly498Glu substitution, and/or Arg/Trp499Lys substitution.
- the DNA or corresponding RNA may be assayed or alternatively the DNA polymerase or surface antigen may be screened for the mutation.
- the detection according to this aspect of the invention may be any nucleic acid-based detection means, for example nucleic acid hybridisation techniques or polymerase chain reaction (PCR).
- the invention further encompasses the use of different assay formats of said nucleic acid-based detection means, including restriction fragment length polymorphism (RFLP), amplified fragment length polymorphism (AFLP), single-strand chain polymorphism (SSCP), amplification and mismatch detection (AMD), interspersed repetitive sequence polymerase chain reaction (IRS-PCR), inverse polymerase chain reaction (iPCR) and reverse transcription polymerase chain reaction (RT-PCR), amongst others.
- RFLP restriction fragment length polymorphism
- AFLP amplified fragment length polymorphism
- SSCP single-strand chain polymorphism
- ATD amplification and mismatch detection
- IFS-PCR interspersed repetitive sequence polymerase chain reaction
- iPCR inverse polymerase chain reaction
- RT-PCR reverse transcription polymerase chain reaction
- the present invention extends to a range of immunologically based assays to detect variant HBV DNA polymerase or surface antigen.
- immunologically based assays to detect variant HBV DNA polymerase or surface antigen.
- assays are based on antibodies directed to naturally occurring HBV DNA polymerase or surface antigen which do not, or substantially do not, interact with the variant HBV DNA polymerase or surface antigen.
- antibodies to a variant HBV DNA polymerase or surface antigen are used which do not or substantially do not, interact with naturally occurring HBV DNA polymerase or surface antigen.
- Monoclonal or polyclonal antibodies may be used although monoclonal antibodies are preferred as they can be produced in large quantity and in a homogenous form.
- a wide range of immunoassay techniques are available such as described in U.S. Pat. Nos. 4,016,043, 4,424,279 and 4,018,653.
- the detection of amino acid variants of DNA polymerase is conveniently accomplished by reference to the consensus amino acid sequence shown in FIG. 4 .
- the polymorphisms shown represent the variations shown in various data bases for active pathogenic HBV strains. Where an HBV variant comprises an amino acid different to what is represented, then such an isolate is considered a putative HBV variant having an altered DNA polymerase activity.
- another aspect of the present invention contemplates a method for determining whether an HBV isolate encodes a variant DNA polymerase, said method comprising determining the amino acid sequence of its DNA polymerase directly or via a nucleotide sequence and comparing same to the amino acid sequence below (SEQ ID NO:29):
- the present invention further contemplates agents which mask the nucleoside analogue resistance mutation. Such agents will be particularly useful in long term treatment by nucleoside analogues.
- the agents may be DNA or RNA or proteinaceous or non-proteinaceous chemical molecules. Natural product screening such as from plants, coral and microorganisms is also contemplated as a useful potential source of masking agents.
- the agents may be in isolated form or in the form of a pharmaceutical composition and may be administered sequentially or simultaneously with the nucleoside analogue.
- kits for assays for variant HBV may, for example, contain the reagents from PCR or other nucleic acid hybridisation technology or reagents for immunologically based detection techniques.
- FIG. 1 is a diagrammatic representation showing the partially double stranded DNA HBV genome showing the overlapping open reading frames encoding surface (S), core (C), polymerase (P) and X gene.
- FIG. 2 is a graphical representation showing serum biochemical (ALT) and virological (HBV DNA) profile in the transplant patient and the responses following the introduction of various antiviral treatment programs.
- Treatment GCV+PFF, GCV and FCV[I] and FCV[II] are described in detail in the examples.
- Treatment GCV+PFF is ganciclovir plus foscarnet combination (12)
- treatment GCV is parenteral ganciclovir maintenance therapy
- treatment FCV[I] and FCV[II] is oral famciclovir therapy at a dose of 250 mg or 500 mg twice daily, respectively. The day each therapy commenced is shown in brackets.
- ALT and HBV DNA ( ⁇ - ⁇ ) responses are plotted against time from the commencement of antiviral therapy at 6 months post-OLT.
- the five key time points for the sequence analysis, pre-treatment (PRE-) and days 87, 600, 816 and 1329 post antiviral treatment are shown.
- FIG. 3 is a representation showing amino acid alignment of the RNA dependent DNA polymerase sequence motifs from HBV, pre-treatment with famciclovir and 370 days post-treatment (total antiviral therapy of 816 days), with the woodchuck hepatitis virus (WHV), human immunodeficiency virus (HIV), and the comparable regions with the DNA polymerase of herpes simplex virus (HSV) (13, 14).
- the conserved asparagine (D) and glycine (G) residues within the polymerase motifs are in bold type and the amino acid changes found after famciclovir treatment are in bold type and underlined.
- the location of the mutated amino acid residues within HBV polymerase are shown.
- the bold face underlined glycine (G) residue in the HSV polymerase becomes a cysteine (C) during penciclovir treatment (15).
- FIG. 4 is a representation showing conserved regions of domain A to E (underlined) of HBV.
- M in YMDD is designated amino acid number 550. * indicates greater than three amino acid possibilities at this position of the consensus sequence.
- FIG. 5 is a representation showing amino acid alignment of the RNA dependent DNA polymerase sequence motifs from HBV, noting the amino acid changes which have been selected for in the presence of famciclovir and 3TC.
- HBV concensus sequence was derived from published sequences in Genebank/Entrez. The conserved asparagine (D) and glycine (G) residues within the polymerase motifs are in bold type. The amino acid changes found after famciclovir treatment are in bold green type and underlined and after 3TC are in bold blue type and are underlined.
- FIG. 6 is a representation showing the nucleotide sequence of an HBV variant and corresponding amino acid sequences for HBV DNA polymerase and HBV surface antigen showing in bold mutations G498E in the polymerase and D144E and G145R in the surface antigen.
- the inventors sequenced the HBV polymerase and X open reading frames from a series of isolates from a patient who received antiviral therapy for almost 4 years following post liver transplant recurrence of HBV infection ( FIG. 2 ).
- the patient male, aged 42 years was transplanted because of end-stage liver failure due to chronic HBV infection.
- Antiviral treatment was commenced approximately 6 months post-OLT.
- the patient received intravenous (iv) ganciclovir (GCV; 10 mg/kg/day) in combination with iv foscarnet (PFF; 50-125 mg/kg/day; the dose depending on renal function) (12). This is the treatment of GCV+PFF described in FIG. 1 which lasted for 86 days.
- FIG. 2 shows the alanine amino transferase (ALT) and HBV DNA levels over the entire course of antiviral treatment.
- Patient B was retransplanted for pre-core mutant associated HBV-related allograph loss 14 months after the initial liver transplant.
- Antiviral treatment with GCV (7.5 mg/kg/day) was given for 10 months and then ceased. This was followed by oral famciclovir therapy given (500 mg 3 times/day).
- HBV polymerase gene was sequenced from a serum HBV sample taken post-transplantation after 850 days FCV therapy.
- the regions encompassing the catalytic domains of the HBV polymerase were sequenced from a serum sample pretransplant prior to FCV treatment.
- This patient is treated with famciclovir in which resistance mutation is selected.
- Hepatitis B surface antigen HbsAg
- hepatitis B e antigen HbeAg
- anti-HBe hepatitis B core antigen
- HbcAg hepatitis B core antigen specific IgG and IgM
- hepatitis A specific IgM hepatitis delta antigen and antibody
- anti-hepatitis C virus antibody were measured using commercially available immunoassays (Abbott Laboratories, North Chicago, Ill.). Only the HBV markers were positive.
- PCR polymerase chain reaction
- the sense primer was 5N-CCT TTA CCC CGT TGC CCG GC-3N [SEQ ID NO:3] (nt 2055 to 2074) and the antisense primer 5N-GCT CCA AAT TCT TTA TA-3N [SEQ ID NO:4] (nt 2831 to 2847). All nt are numbered from the start of the polymerase gene.
- reaction was carried out using 5 ⁇ l of the extracted DNA as template, 1.5 U of Taq polymerase (Perkin Elmer Cetus, Norwalk, Conn.), 1 ⁇ mol/L of sense and antisense primers, 200 ⁇ mol/L each of deoxynucleoside triphosphates, 50 mmol/L Kcl, 3.5 mmol/L MgCl, 10 mmol/L Tris-Hcl (pH 8.3) and 0.01% w/v gelatin.
- Amplification was achieved by 40 cycles of denaturation (94 EC for 1 min), annealing (55 EC for 1 min) and extension (72 EC for 1.5 min), followed by a final extension of 7 min (Perkin-Elmer Cetus, Norwalk, Conn.).
- the PCR product was analysed by gel electrophoresis through 1.5% w/v agarose and visualised by UV irradiation after staining with ethidium bromide.
- Sequencing of the polymerase and X genes of HBV DNA The specific amplified product was purified using Geneclean II (BIO 101 Inc., La Jolla, Calif.) and directly sequenced using Sequenase version 2.0 (United States Biochemical Corp., Cleveland, Ohio). The PCR primers were used as sequencing primers and internal primers were additionally synthesised to sequence the internal regions of the PCR products.
- the DNA was purified with Geneclean II and ligated using T4 DNA ligase (New England Biolabs, Beverly, Mass.) into a Sma I—digested dephosphorylated pUC18 plasmid (Pharmacia Biotech, NJ). Clones were directly sequence as above.
- Samples of serum (100 ⁇ l) were applied to a 20% w/v sucrose cushion in THE (20 mmol/L Tris-HCl pH 7.4, 150 mmol/L NaCl 2 1 mmol/L EDTA) and centrifuged at 200,000 g for 3 hr at 101 C using an SW41 rotor in a Beckman Model L8 ultracentrifuge. The pellet was resuspended in 50 mmol/L TRIS-HCl pH 7.5 containing 1.5% v/v Triton-X100, 100 mmol/L Kcl and 0.01% v/v 2-mercaptoethanol and allowed to stand overnight at 41 C.
- HBV DNA post-OLT Upon commencement of the antiviral treatment strategy GCV+PFF, the level of HBV DNA post-OLT decreased from over 100,000 pg/ml to 10,800 pg/ml by day 87 ( FIG. 1 ). This reduction in viraemia was associated with clinical, biochemical and histological improvement (12). Maintenance famciclovir therapy (treatment GCV) resulted in fluctuating levels of HBV DNA over the ensuring 359 days with two peaks of HBV DNA observed. The switch to oral famciclovir on day 446 was also associated with a rise in HBV DNA, but this was likely to have been the result of insufficient dosing (FCV[I] in FIG. 2 ) rather than a breakthrough in treatment.
- FCV[I] insufficient dosing
- HBV DNA Following dose increase to FCV [II] on day 500, there was a decrease in HBV DNA. However, the level of HBV DNA gradually rose over time from 3,000 pg/ml on day 600 (154 days of famciclovir), to 8,800 pg/ml on day 816 (370 days famciclovir), peaking at 29,000 pg/ml on day 1302 (856 days of famciclovir), then stabilising at around 12,000 pg/ml on day 1329 (883 days of famciclovir). A students test of the DNA levels during the treatment period from days 816 to days 1329, revealed statistically significant rise. There was a 1.5 to 2 fold rise in ALT levels over the same time interval ( FIG. 2 ) and no change in clinical status.
- the X and the polymerase genes of HBV were sequenced at five time points ( FIG. 2 ). During almost 4 years of the antiviral therapy there were no changes in the X gene compared to the pretreatment sequence. However, there were 5 nt changes detected in the polymerase gene from day 816 and day 1329 samples (Table 1). These changes were detected in separate independent PCR amplifications; furthermore the mutations were detected by sequencing both strands and are therefore unlikely to be the result of PCR generated errors. The nt changes in the polymerase gene were first detected after 816 days of treatment, when the patient had been treated with famciclovir for 370 days.
- FIG. 5 The amino acid changes in HBV isolated from patients B and C are shown in FIG. 5 , and from patient D is shown in FIG. 6 .
- patient A is the same as shown in FIG. 3 .
- HBV patient B
- 3TC lamvudine [6,7]
- HBV patient C-FCV
- All 3TC resistance mutations which developed during treatment with 3TC is shown as HBV (patient C-3TC).
- the sequence analysis showed a mutation (Thr-Ser substitution) in the HBV polymerase gene near the C domain but no mutation was initially detected in the YMDD motif
- a mutation of Met 550 to Ile in the YMDD motif was detected from HBV isolated 32 days (333 days post treatment) after the HBV containing the Thr-Ser substitution was isolated.
- HBV variants are screened for escape mutations.
- These are mutations in surface components such as the HBV surface antigen which reduce the interactivity of the surface component to antibodies or other immunological reagents.
- a single mutation may have multiphenotypic consequences.
- a mutation in the HBV DNA polymerase may also have an affect on the HBV surface antigen.
- Preferred mutations in the HBV surface antigen are in amino acids 118 to 169 and/or 169 to 207 such as D144E or G145R. These correspond to DNA polymerase mutations G498E and V499L.
- a particularly preferred escape mutant and nucleoside analogue resistant mutant has a nucleotide sequence set forth in FIG. 6 with corresponding amino acid sequences for the DNA polymerase and surface antigen.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The present invention relates generally to viral variants exhibiting reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic agents.
Description
- This application is a divisional of Ser. No. 12/117,869 (pending), filed May 9, 2008 (published as US 2010-0203506-A1), which is a continuation of Ser. No. 10/260,451 (abandoned), filed Oct. 1, 2002 (published as US 2003-0124096-A1), which is a divisional of Ser. No. 09/306,420, filed May 6, 1999 (issued as U.S. Pat. No. 6,555,311), which is a U.S. national phase of PCT/AU97/00520, filed Aug. 15, 1997, which claims benefit of Australian Application No. PO 3519, filed Nov. 8, 1996, the entire contents of each of which are hereby incorporated by reference.
- The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B variants exhibiting complete or partial resistance to nucleoside analogues and/or reduced interactivity with antibodies to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic regimes.
- Bibliographic details of the publications numerically referred to in this specification are collected at the end of the description. Sequence Identity Numbers (SEQ ID NOs.) for the nucleotide and amino acid sequences referred to in the specification are defined following the bibliography.
- Throughout this specification, unless the context requires otherwise, the word “comprise”, or variations such as “comprises” or “comprising” or the term “includes” or variations thereof, will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers. In this regard, in construing the claim scope, an embodiment where one or more features is added to any of claim is to be regarded as within the scope of the invention given that the essential features of the invention as claimed are included in such an embodiment.
- Specific mutations in an amino acid sequence are represented herein as AXaa1nXaa2″ where Xaa1 is the original amino acid residue before mutation, n is the residue number and Xaa2 is the mutant amino acid. The abbreviation “Xaa” may be the three letter or single letter amino acid code. The amino acid residues for Hepatitis B virus DNA polymerase are numbered with the residue methionine in the motif Tyr Met Asp Asp (YMDD) being
residue number 550. In the priority document, Australian Patent Application No. PO3519, filed 8 Nov. 1996, the same methionine was designatedresidue 530. The amino acid residues for the DNA polymerase referred to in this specification have been re-numbered accordingly. - Hepatitis B Virus (HBV) can cause debilitating disease conditions and can lead to acute liver failure. HBV is a DNA virus which replicates via an RNA intermediate and utilizes reverse transcription in its replication strategy (1). The HBV genome is of a complex nature having a partially double stranded DNA structure with overlapping open reading frames encoding surface, core, polymerase and X genes. The complex nature of the HBV genome is represented in
FIG. 1 . - The presence of an HBV DNA polymerase has led to the proposition that nucleoside analogues could act as effective anti-viral agents. Examples of nucleoside analogues currently being tested are penciclovir and its oral form famciclovir (2, 3, 4, 5) and lamivudine (6,7). There is potential for such agents to be used in the treatment of chronic HBV infection.
- Peniciclovir has been recently shown to have potent inhibitory activity against duck HBV DNA synthesis in vitro and has been shown to inhibit HBV DNA polymerase-reverse transcriptase activity in vitro (8,9). Similarly, oral famiciclovir has been demonstrated to inhibit intra-hepatic replication of duck HBV virus in vivo (10). In man, famciclovir has been shown to reduce HBV DNA replication in a patient with severe hepatitis B following orthotopic liver transplantation (OLT) (11).
- In work leading up to the present invention, nucleoside analogue antiviral therapy was used to control severe post-OLT recurrence of HBV infection (12). Long term therapy is mandatory where patients are immunosuppressed and the rate of HBV replication is very high. However, under such conditions, as with any long term chemotherapy of infectious agents, there is a potential for development of resistance or reduced sensitivity to the therapeutic agents employed.
- In accordance with the present invention, the inventors have identified variants of HBV with mutations in the HBV DNA polymerase gene which to varying extents reduce the sensitivity of HBV to nucleoside analogues. The identification of these HBV variants is important for the development of assays to monitor nucleoside analogue therapeutic regimes and to screen for agents which can mask the effects of the mutation. In addition, since the HBV genome comprises a series of overlapping open reading frames, a nucleotide mutation in one open reading frame can affect translation products in another open reading frame. In further accordance with the present invention, the inventors have observed mutations which reduce the interactivity of immunological reagents, such as antibodies and immune cells, to viral surface components. Such viral variants are referred to herein as “escape mutants” since they potentially escape existing immunological memory.
- Accordingly, one aspect of the present invention is directed to a variant of an isolated DNA virus which replicates via an RNA intermediate wherein said variant comprises a nucleotide mutation in a gene encoding a DNA polymerase resulting in at least one amino acid addition, substitution and/or deletion to said DNA polymerase.
- Another aspect of the present invention provides a variant of an isolated DNA virus which replicates via an RNA intermediate wherein said variant comprises a nucleotide mutation in a gene encoding a viral surface component resulting in at least one amino acid addition, substitution and/or deletion in said viral surface component.
- Still a further aspect of the present invention is directed to a variant of an isolated DNA virus which replicates via an RNA intermediate at least wherein said variant comprises a nucleotide mutation in an overlapping portion of at least two open reading frames resulting in an amino acid addition, substitution and/or deletion to translation products of said open reading frames.
- Preferably, the DNA virus is a hepatitis virus or a related virus and is most preferably HBV.
- A “related virus” in accordance with the present invention is one related at the genetic, immunological, epidemiological and/or biochemical levels.
- Preferably, the mutation in the DNA polymerase results in decreased sensitivity of the HBV to a nucleoside analogue.
- Preferably, the mutation in the viral surface component reduces the interactivity of immunological reagents such as antibodies and immune cells to the viral surface component. Most preferably, the viral surface component is a viral surface antigen. The reduction in the interactivity of immunological reagents to a viral surface component generally includes the absence of immunological memory to recognise or substantially recognise the viral surface component.
- A viral variant may, in accordance with a preferred aspect of the present invention, carry mutation only in the DNA polymerase or the surface antigen or may carry a mutation in both molecules. The term “mutation” is to be read in its broadest context and includes a silent mutation not substantially affecting the normal function of the DNA polymerase or surface antigen or may be an active mutation having the effect of inducing nucleoside analogue resistance or an escape mutant phenotype. Where multiple mutations occur in accordance with the present invention or where multiple phenotypes result from a single mutation, at least one mutation must be active or the virus must exhibit at least one altered phenotype such as nucleoside analogue resistance or reduced immunological interactivity to the surface antigen.
- Regions of the HBV polymerase show amino acid similarity with other RNA-dependent DNA polymerases and RNA-dependent polymerases (13). In this specification, reference is made to the conserved regions defined by Poch et al (13) as domains B and C.
- Preferably, the mutation results in an altered amino acid sequence in the B domain and/or C domain or regions proximal thereto of the HBV DNA polymerase. The present invention does not extend to a mutation alone in the YMDD motif of the C domain of the HBV DNA polymerase although such a mutation is contemplated by the present invention if it occurs in combination with one or more mutations in another location.
- The mutation in the viral surface component is preferably in one or more amino acid residues within the major hydrophilic regions of the protein, in particular within the amino acid sequence 118-169 of the HBV viral surface antigen and also the regions from amino acids sequence 169 to 207 which are on the external surface of the protein.
- According to a preferred aspect of the present invention, there is provided an HBV variant comprising a mutation in the nucleotide sequence encoding a DNA polymerase resulting in an amino acid addition, substitution and/or deletion in said DNA polymerase in its B domain and/or C domain or in a region proximal thereto, provided said mutation is not in the YMDD motif of the C domain alone, and wherein said variant exhibits decreased sensitivity to a nucleoside analogue.
- Another preferred aspect of the present invention contemplates an HBV variant comprising a mutation in the nucleotide sequence encoding a viral surface component resulting in an amino acid addition, substitution and/or deletion in said viral surface component in a region corresponding to the B domain and/or C domain of HBV DNA polymerase or a region proximal to the B domain and/or C domain of HBV DNA polymerase and wherein said variant exhibits decreased interactivity of immunological reagents to said viral surface component.
- Yet another preferred aspect of the present invention relates to an HBV variant comprising a mutation in the nucleotide sequence encoding a viral surface component resulting in an amino acid addition, substitution and/or addition in said viral surface component in a region defined by amino acids 118 to 169 and also 169 to 207 of the HBV surface antigen or functionally equivalent region wherein said variant exhibits decreased interactivity of immunological reagents to said viral surface component.
- Still yet another aspect of the present invention is directed to an HBV variant comprising a mutation in an overlapping open reading frame in its genome wherein said mutation is in the B and/or C domain of DNA polymerase provided that it is not in the YMDD (SEQ ID NO 30) motif of the C domain alone; and in the overlapping region corresponding to amino acids 118 to 169 and also 169 to 207 or equivalent of HBV surface antigen and wherein said variant exhibits decreased sensitivity to a nucleotide analogue and exhibits decreased interactivity to immunological reagents specific to HBV surface antigens.
- The viral variant exhibiting reduced interactivity to immunological reagents is an escape mutant since antibodies or other immunological response to HBV from a prior exposure to the virus or following vaccination are no longer effective in targeting a viral surface component since the mutation has altered a B- and/or T-cell epitope on the surface antigen.
- The nucleoside analogues contemplated by the present invention include penciclovir and its oral form famciclovir as well as lamivudine (3TC). Different variants may be resistant to different nucleoside analogues. For example, in one embodiment, a variant in the B domain of HBV DNA polymerase may be resistant to famciclovir whereas a variant in the C domain may be resistant to 3TC.
- The B domain is considered to comprise
amino acid residues 505 to 529 of HBV DNA polymerase. This sequence is represented as follows (SEQ ID NO 24): -
S/A H PI I/V LGFRK I/L PMG V/G GLSPFLLAQF - Reference to the B domain includes reference to proximal regions which includes up to about 20 amino acids on either side of the domain. Preferably, the mutation is in one or more of the following amino acids (SEQ ID NO 25):
-
Q/K T Y/F G R/W KLHL Y/L S/A HPI I/V LGFRK I/L PMG V/G GLSPFLLAQFTSAI C/L S - The C domain comprises
amino acids 546 to 556 as follows (SEQ ID NO 26): -
A/V F S/A YMDD V/L/M VLG - This includes the YMDD domain in which the methione residue is considered residue 550 (formally regarded as residue number 530). The residue numbering in this specification has been adjusted according to the new numbering system where the methione of YMDD is 550.
- Reference to the C domain includes proximal regions of up to 20 amino acids either side of the domain.
- The term Aresistance≅is used in its most general sense and includes total resistance or partial resistance or decreased sensitivity to a nucleoside analogue.
- Preferably, the variants are in isolated form such that they have undergone at least one purification step away from naturally occurring body fluid. Alternatively, the variants may be maintained in isolated body fluid or may be in DNA form. The present invention also contemplates infectious molecular clones comprising the genome or parts thereof from a variant HBV.
- Preferred mutations in the HBV DNA polymerase include one or more of Gly498Glu, Arg/Trp499Lys, Thr530Ser, Ile509Val, Phe512Leu, Val519Leu, Pro523Leu, Leu526Met, Ile533Leu, Met550Val/Ile and/or Ser559Thr. Preferred mutations in the HBV surface antigen include one or more of Asp144Glu and/or Gly145Arg. These correspond to
positions 498 and 499 of DNA polymerase, respectively. More preferably, the variants contain two or more of the above-mentioned mutations. - One particular mutant HBV has the nucleotide sequence set forth in SEQ ID NO:17 and exhibits a multiphenotypic mutation rendering the DNA polymerase resistant to nucleoside analogues and an altered surface antigen such that it has reduced interactivity with antibodies to HBV surface antigen. The mutation is G498E in the DNA polymerase open reading frame as D144E and G145R in the surface antigen. This results from a double mutation in nucleotide numbers 226 and 227 of SEQ ID NO:17 to G and A. The polymerase protein of HBV is also similar to the DNA polymerase of Herpes Simplex Virus (HSV) (see
FIG. 3 for alignment). A mutation (Gly841Cys) in the HSV polymerase gene was selected for in the presence of famciclovir (15). This mutation occurs in the same position as the G498E mutation of the HBV polymerase. - The present invention extends to the nucleotide sequence set forth in SEQ ID NO:17 as well as a nucleotide sequence having at least 60% similarity thereto and which carries a double mutation in the amino acid sequence of DNA polymerase and the HBV surface antigen. Accordingly, the present invention is directed to an HBV having the nucleotide sequence as set forth in SEQ ID NO:17 or a derivative thereof having a single or multiple nucleotide addition, substitution and/or deletion thereto such as a nucleotide sequence having at least 60% similarity to SEQ ID NO:17. A derivative includes parts, fragments, portions and homologues of SEQ ID NO:17. This aspect of the present invention also extends to a nucleotide sequence capable of hybridizing under low stringency conditions at 421C to SEQ ID NO:17.
- Reference herein to a low stringency at 42 EC includes and encompasses from at least about 1% v/v to at least about 15% v/v formamide and from at least about 1M to at least about 2M salt for hybridisation, and at least about 1M to at least about 2M salt for washing conditions. Alternative stringency conditions may be applied where necessary, such as medium stringency, which includes and encompasses from at least about 16% v/v to at least about 30% v/v formamide and from at least about 0.5M to at least about 0.9M salt for hybridisation, and at least about 0.5M to at least about 0.9M salt for washing conditions, or high stringency, which includes and encompasses from at least about 31% v/v to at least about 50% v/v formamide and from at least about 0.01M to at least about 0.15M salt for hybridisation, and at least about 0.01M to at least about 0.15M salt for washing conditions.
- Accordingly, another aspect of the present invention contemplates a variant HBV exhibiting reduced sensitivity to a nucleoside analogue and reduced interactivity to an antibody to wild-type HBV surface antigen, said HBV variant characterised by one or more of the following characteristics:
- (i) a nucleotide sequence of its genome as set forth in SEQ ID NO:17 or a sequence having at least 60% similarity thereto;
- (ii) a nucleotide sequence capable of hybridising to SEQ ID NO:17 under low stringency conditions at 421 C;
- (iii) a mutation in an overlapping portion of open reading frames for DNA polymerization and HBV surface antigen; and
- (iv) a mutation in the B and/or C domain of HBV DNA polymerase and is a region corresponding to amino acids 118 to 169 and also 169 to 207 of HBV surface antigen.
- According to another aspect of the present invention, there is provided a variant HBV comprising a nucleotide sequence which encodes a DNA polymerase having the amino acid sequence (SEQ ID NO:27 and SEQ ID NO:28):
-
X1HPIX2LGX3RKX4PMGX5GLSX6FLX7AQFTSAX8X9 . . . X10FX11YX12DDX13VLGAX14X15 - wherein X1 is S or A;
-
- X2 is I or V;
- X3 is F or L;
- X4 is I or L;
- X5 is L or V or G;
- X6 is P or L;
- X7 is L or M;
- X8 is I or L;
- X9 is C or L;
- X10 is A or V;
- X11 is S or A;
- X12 is M or I or V;
- X13 is V or L or M;
- X14 is K or R; and/or
- X15 S or T;
- and wherein said variant exhibits reduced sensitivity to a nucleoside sensitivity to a nucleoside analogue, such as famciclovir (penciclovir) and/or lamivudine (3TC).
- Another embodiment of the present invention is directed to a variant HBV comprising a nucleotide sequence which encodes a surface antigen having at least one amino acid substitution, addition and/or deletion to amino acid residue numbers 118 to 169 and also 169 to 207 of said surface antigen which corresponds to a DNA polymerase having the amino acid sequence (SEQ ID NO:42 and SEQ ID NO:43):
-
X16TX17X18X19KLHLX20X21HPIX22LGX3RKX4PMGX5GLSX6FLX7AQFTSAX8X9 . . . X10FX11YX12DDX13VLGAX14X15 - wherein: X16 is Q or K;
-
- X17 is Y or F;
- X18 is G or E;
- X19 is R or W or K;
- X20 is Y or L;
- X21 is S or A;
- X22 is I or V;
- X3 is F or L;
- X4 is I or L;
- X5 is L or V or G;
- X6 is P or L;
- X7 is L or M;
- X8 is I or L;
- X9 is C or L;
- X10 is A or V;
- X11 is S or A;
- X12 is M or I or V;
- X13 is V or L or M;
- X14 is K or R; and/or
- X15 S or T;
- and wherein said variant exhibits reduced interactivity with immunological reagents, such as an antibody, to said surface antigen.
- Examples of preferred variants comprise the amino acid sequences shown in
FIG. 4 . An example of a particularly preferred mutant is shown inFIG. 5 (SEQ ID NO:17). - The identification of the variants of the present invention permits the generation of a range of assays to detect such variants. The detection of such variants may be important in identifying resistant variants to determine the appropriate form of chemotherapy and/or to monitor vaccination protocols.
- Accordingly, another aspect of the present invention contemplates a method for determining the potential for an HBV to exhibit reduced sensitivity to a nucleoside analogue, said method comprising isolating DNA or corresponding mRNA from said HBV and screening for a mutation in the nucleotide sequence encoding HBV DNA polymerase resulting in at least one amino acid substitution, deletion and/or addition in the B domain or C domain or a region proximal thereto of said DNA polymerase wherein the presence of such a mutation is an indication of the likelihood of resistance to said nucleoside analogue.
- A further aspect of the present invention provides a method for determining the potential for an HBV to exhibit reduced interactivity to antibody to HBV surface antigen, said method comprising isolating DNA or corresponding mRNA from said HBV and screening for a mutation in the nucleotide sequence encoding HBV surface antigen resulting in at least one amino acid substitution, deletion and/or addition in amino acids 118 to 169 and/or 169 to 207 of said surface antigen or a region proximal thereto of said surface antigen wherein the presence of such a mutation is an indication of the likelihood of reducing interactivity of said antibodies to said mutated surface antigen.
- Preferably, the assay determines a mutation resulting in a Glu/Val519Leu substitution and/or a Leu526Met substitution and/or a Pro523Leu substitution and/or a S559T substitution, and/or Gly498Glu substitution, and/or Arg/Trp499Lys substitution.
- The DNA or corresponding RNA may be assayed or alternatively the DNA polymerase or surface antigen may be screened for the mutation.
- The detection according to this aspect of the invention may be any nucleic acid-based detection means, for example nucleic acid hybridisation techniques or polymerase chain reaction (PCR). The invention further encompasses the use of different assay formats of said nucleic acid-based detection means, including restriction fragment length polymorphism (RFLP), amplified fragment length polymorphism (AFLP), single-strand chain polymorphism (SSCP), amplification and mismatch detection (AMD), interspersed repetitive sequence polymerase chain reaction (IRS-PCR), inverse polymerase chain reaction (iPCR) and reverse transcription polymerase chain reaction (RT-PCR), amongst others.
- The present invention extends to a range of immunologically based assays to detect variant HBV DNA polymerase or surface antigen. These assays are based on antibodies directed to naturally occurring HBV DNA polymerase or surface antigen which do not, or substantially do not, interact with the variant HBV DNA polymerase or surface antigen. Alternatively, antibodies to a variant HBV DNA polymerase or surface antigen are used which do not or substantially do not, interact with naturally occurring HBV DNA polymerase or surface antigen.
- Monoclonal or polyclonal antibodies may be used although monoclonal antibodies are preferred as they can be produced in large quantity and in a homogenous form. A wide range of immunoassay techniques are available such as described in U.S. Pat. Nos. 4,016,043, 4,424,279 and 4,018,653.
- The detection of amino acid variants of DNA polymerase is conveniently accomplished by reference to the consensus amino acid sequence shown in
FIG. 4 . The polymorphisms shown represent the variations shown in various data bases for active pathogenic HBV strains. Where an HBV variant comprises an amino acid different to what is represented, then such an isolate is considered a putative HBV variant having an altered DNA polymerase activity. - Accordingly, another aspect of the present invention contemplates a method for determining whether an HBV isolate encodes a variant DNA polymerase, said method comprising determining the amino acid sequence of its DNA polymerase directly or via a nucleotide sequence and comparing same to the amino acid sequence below (SEQ ID NO:29):
-
DOMAIN A 421 430 440 450 SN DLSWLSLD VSAAFYH I PPL HPAAMPHLLI V GSSGLS DRYVA 460 470 480 490 RLSST NSR NNI*N NYHQH Y G R***D NLH D N S YCSRN QLYVS LL MLLYK QTY FGR W DOMAIN B 500 510 520 530 KLHLYL S AHPII V LGFRKI LPMGV G GLSPFLLAQF TSAIC L A S V M V T R C R DOMAIN C 540 550 560 AFF PHCL V A VFS AY MDDVLMVLGA K R S T V G Q EHLSRES FLF Y T A A S DOMAIN D DOMAIN E 570 580 590 600 V I T C N S F VLLS D L VGI HLNPN QKTKRW GYSLNFMGYV II G - where the presence of a different amino acid from the consensus sequence indicates a putative HBV variant.
- The present invention further contemplates agents which mask the nucleoside analogue resistance mutation. Such agents will be particularly useful in long term treatment by nucleoside analogues. The agents may be DNA or RNA or proteinaceous or non-proteinaceous chemical molecules. Natural product screening such as from plants, coral and microorganisms is also contemplated as a useful potential source of masking agents. The agents may be in isolated form or in the form of a pharmaceutical composition and may be administered sequentially or simultaneously with the nucleoside analogue.
- The subject invention extends to kits for assays for variant HBV. Such kits may, for example, contain the reagents from PCR or other nucleic acid hybridisation technology or reagents for immunologically based detection techniques.
- The present invention is further described by the following non-limiting figures and examples.
- In the figures:
-
FIG. 1 is a diagrammatic representation showing the partially double stranded DNA HBV genome showing the overlapping open reading frames encoding surface (S), core (C), polymerase (P) and X gene. -
FIG. 2 is a graphical representation showing serum biochemical (ALT) and virological (HBV DNA) profile in the transplant patient and the responses following the introduction of various antiviral treatment programs. Treatment GCV+PFF, GCV and FCV[I] and FCV[II] are described in detail in the examples. Treatment GCV+PFF is ganciclovir plus foscarnet combination (12), treatment GCV is parenteral ganciclovir maintenance therapy and treatment FCV[I] and FCV[II] is oral famciclovir therapy at a dose of 250 mg or 500 mg twice daily, respectively. The day each therapy commenced is shown in brackets. The ALT (X-X) and the HBV DNA (˜-˜) responses are plotted against time from the commencement of antiviral therapy at 6 months post-OLT. The five key time points for the sequence analysis, pre-treatment (PRE-) anddays -
FIG. 3 is a representation showing amino acid alignment of the RNA dependent DNA polymerase sequence motifs from HBV, pre-treatment with famciclovir and 370 days post-treatment (total antiviral therapy of 816 days), with the woodchuck hepatitis virus (WHV), human immunodeficiency virus (HIV), and the comparable regions with the DNA polymerase of herpes simplex virus (HSV) (13, 14). The conserved asparagine (D) and glycine (G) residues within the polymerase motifs are in bold type and the amino acid changes found after famciclovir treatment are in bold type and underlined. The location of the mutated amino acid residues within HBV polymerase are shown. The bold face underlined glycine (G) residue in the HSV polymerase becomes a cysteine (C) during penciclovir treatment (15). -
FIG. 4 is a representation showing conserved regions of domain A to E (underlined) of HBV. M in YMDD is designatedamino acid number 550. * indicates greater than three amino acid possibilities at this position of the consensus sequence. -
FIG. 5 is a representation showing amino acid alignment of the RNA dependent DNA polymerase sequence motifs from HBV, noting the amino acid changes which have been selected for in the presence of famciclovir and 3TC. HBV concensus sequence was derived from published sequences in Genebank/Entrez. The conserved asparagine (D) and glycine (G) residues within the polymerase motifs are in bold type. The amino acid changes found after famciclovir treatment are in bold green type and underlined and after 3TC are in bold blue type and are underlined. The amino acid sequence of the HBV isolated from patient A and patient B, during famicilovir treatment and from Patient C who did not respond to famciclovir and was later treated with 3TC in which a resistance mutation was selected (3TC 2). The published 3TC changes detected by Ling et al (16) is shown in3TC 1. -
FIG. 6 is a representation showing the nucleotide sequence of an HBV variant and corresponding amino acid sequences for HBV DNA polymerase and HBV surface antigen showing in bold mutations G498E in the polymerase and D144E and G145R in the surface antigen. - 1. Patient A
- The inventors sequenced the HBV polymerase and X open reading frames from a series of isolates from a patient who received antiviral therapy for almost 4 years following post liver transplant recurrence of HBV infection (
FIG. 2 ). - The patient (male, aged 42 years) was transplanted because of end-stage liver failure due to chronic HBV infection. The initial post transplant course was unremarkable but by 5 months there was evidence of recurrent infection and very high levels of viral replication and deteriorating liver function (12). The histological picture was consistent with fibrosing cholestatic hepatitis. Antiviral treatment was commenced approximately 6 months post-OLT. Initially, the patient received intravenous (iv) ganciclovir (GCV; 10 mg/kg/day) in combination with iv foscarnet (PFF; 50-125 mg/kg/day; the dose depending on renal function) (12). This is the treatment of GCV+PFF described in
FIG. 1 which lasted for 86 days. Maintenance iv GCV (3.3-6.7 mg/kg/day) three times per week was commenced onday 87 of antiviral treatment (GCV inFIG. 1 ). Oral famciclovir (250 mg, twice daily) was commenced onday 446 of therapy (FCV [I] inFIG. 1 ) which was increased to 500 mg twice daily (FCV [II] inFIG. 1 ) onday 500. The patient is currently on this treatment regime. The clinical and virological details of this patient preceding famciclovir therapy have been reported (12). - Serum samples were routinely collected and stored at −70 EC. Informed consent was obtained from the patient to use these samples for research purposes.
FIG. 2 shows the alanine amino transferase (ALT) and HBV DNA levels over the entire course of antiviral treatment. The 5 samples chosen for additional studies cover a period of almost four years. - 2. Patient B
- Patient B was retransplanted for pre-core mutant associated HBV-related allograph loss 14 months after the initial liver transplant. Antiviral treatment with GCV (7.5 mg/kg/day) was given for 10 months and then ceased. This was followed by oral famciclovir therapy given (500 mg 3 times/day).
- From patient B the entire HBV polymerase gene was sequenced from a serum HBV sample taken post-transplantation after 850 days FCV therapy. The regions encompassing the catalytic domains of the HBV polymerase were sequenced from a serum sample pretransplant prior to FCV treatment.
- 3. Patient C
- This patient did not respond to famciclovir and was later treated with lamivudine (3TC) (6, 7) in which a resistance mutation was selected.
- 4. Patient D
- This patient is treated with famciclovir in which resistance mutation is selected.
- Hepatitis B surface antigen (HbsAg), hepatitis B e antigen (HbeAg), anti-HBe, hepatitis B core antigen (HbcAg) specific IgG and IgM, hepatitis A specific IgM, hepatitis delta antigen and antibody, and anti-hepatitis C virus antibody were measured using commercially available immunoassays (Abbott Laboratories, North Chicago, Ill.). Only the HBV markers were positive. Hepatitis B viral DNA levels were measured and quantified using a capture hybridisation assay according to the manufacturer=s directions (Digene Diagnostics Inc., Beltsville, Md.). This patient was infected with a pre-core HBV mutant pre-OLT (12) and this status did not change post-OLT.
- 1. Extraction of DNA from sera: Aliquots of 50 Φl of sera were mixed with 150 Φl TE (10 mmol/L Tris-HCl (pH 7.5), 2 mmol/L EDTA), 1% w/v sodium dodecyl sulfate and 1 mg/ml pronase and incubated at 37 EC for 2 hours. DNA was deproteinised by phenol/chloroform, precipitated with isopropanol and dissolved in 25 Φl nuclease-free water.
- 2. Amplification of the viral polymerase and X genes by polymerase chain reaction (PCR): Oligonucleotides were synthesised by Bresatec, Adelaide, Australia. For amplification of the polymerase gene, the sense primer was 5N-GGA GTG TGG ATT CGC ACT CC-3N [SEQ ID NO:1] (nucleotides [nt] −40 to −21) and the antisense primer was 5N-GCT CCA AAT TCT TTA TA-3N [SEQ ID NO:2] (nt 2831 to 2847). For amplification of the X gene, the sense primer was 5N-CCT TTA CCC CGT TGC CCG GC-3N [SEQ ID NO:3] (nt 2055 to 2074) and the antisense primer 5N-GCT CCA AAT TCT TTA TA-3N [SEQ ID NO:4] (nt 2831 to 2847). All nt are numbered from the start of the polymerase gene. Each reaction was carried out using 5 Φl of the extracted DNA as template, 1.5 U of Taq polymerase (Perkin Elmer Cetus, Norwalk, Conn.), 1 Φmol/L of sense and antisense primers, 200 Φmol/L each of deoxynucleoside triphosphates, 50 mmol/L Kcl, 3.5 mmol/L MgCl, 10 mmol/L Tris-Hcl (pH 8.3) and 0.01% w/v gelatin. Amplification was achieved by 40 cycles of denaturation (94 EC for 1 min), annealing (55 EC for 1 min) and extension (72 EC for 1.5 min), followed by a final extension of 7 min (Perkin-Elmer Cetus, Norwalk, Conn.). The PCR product was analysed by gel electrophoresis through 1.5% w/v agarose and visualised by UV irradiation after staining with ethidium bromide.
- 3. Sequencing of the polymerase and X genes of HBV DNA: The specific amplified product was purified using Geneclean II (BIO 101 Inc., La Jolla, Calif.) and directly sequenced using Sequenase version 2.0 (United States Biochemical Corp., Cleveland, Ohio). The PCR primers were used as sequencing primers and internal primers were additionally synthesised to sequence the internal regions of the PCR products. The following internal and sequencing primers were used 5N-GCC GCG TCG CAG AAG ATC TCA AT-3N [SEQ ID NO:5] (nt 104-126), 5N-GGT TCT ATC CTA ACC TTA CC-3N [SEQ ID NO:6] (nt 341-360), 5N-GCC TCA TTT TGT GGG TCA CCA TA-3N [SEQ ID NO:7] (nt 496-518), 5N-TGG GGG TGG AGC CCT CAG GCT-3N [SEQ ID NO:8] (nt 731-751), 5N-CAC AAC ATT CCA CCA AGC TC-3N [SEQ ID NO:9] (nt 879-899), 5N-AAA TTC GCA GTC CCC AAC-3N [SEQ ID NO:10] (nt 1183-1195), 5N-GTT TCC CTC TTC TTG CTG T-3N [SEQ ID NO:11] (nt 1429-1447), 5N-TTT TCT TTT GTC TTT GGG TAT-3N [SEQ ID NO:12] (nt 1683-1703) 5N-CCA ACT TAC AAG GCC TTT CTG-3N [SEQ ID NO:13] (nt 1978-1999), 5N-CAT CGT TTC CAT GGC TGC TAG GC-3N [SEQ ID NO:14] (nt 2239-2262).
- 4. Cloning of the HBV polymerase gene into pUC18: Due to the small amount of HBV DNA in the samples, the region encompassing nt 1429 to 1703 from the HBV polymerase gene were amplified by PCR using the primers-5N-GTT TCC CTC TTC TTG CTG T-3N [SEQ ID NO:15] (nt 1429-1447) and 5N ATA CCC AAA GAC AAA AGA AAA-3N [SEQ ID NO:16] (nt 1703-1683), before cloning. The DNA was purified with Geneclean II and ligated using T4 DNA ligase (New England Biolabs, Beverly, Mass.) into a Sma I—digested dephosphorylated pUC18 plasmid (Pharmacia Biotech, NJ). Clones were directly sequence as above.
- Samples of serum (100 Φl) were applied to a 20% w/v sucrose cushion in THE (20 mmol/L Tris-HCl pH 7.4, 150 mmol/
L NaCl 2 1 mmol/L EDTA) and centrifuged at 200,000 g for 3 hr at 101 C using an SW41 rotor in a Beckman Model L8 ultracentrifuge. The pellet was resuspended in 50 mmol/L TRIS-HCl pH 7.5 containing 1.5% v/v Triton-X100, 100 mmol/L Kcl and 0.01% v/v 2-mercaptoethanol and allowed to stand overnight at 41 C. Small aliquots of the suspension were assayed for endogenous HBV DNA polymerase activity essentially as described by Price et al (16). Each assay was performed in a total volume of 30 Φl which contained 20 Φl of the partly purified HBV and (final concentrations) 30 mmol/L Tris-HCl pH 7.5, 30 mmol/L MgCl2, 10 Φmol/L each dATP, dTTP and dGTP, and 0.01 ΦM [α-32P]-dCTP (3,000 Ci/mmol) (Dupont NEN, Boston, Mass.). To test for penciclovir triphosphate (PCV-TP) sensitivity, paired assays were performed on each sample, with an excess (100 Φmol/L penciclovir-triphosphate included in the reaction mixture in one assay of each pair. After 2 hr at 371 C, reactions were stopped by spotting 20 Φl aliquots of each reaction mix onto 25 mm diameter glass fibre discs (Advantex, Tokyo, Japan) which had been pre-soaked in 10% w/v trichloroacetic acid (TCA). Discs were dried before washing in ice-cold 10% w/v TCA containing 10 mmol/L sodium pyrophosphate. Three further 10 min washes in cold 5% v/v TCA followed. The washed discs were finally rinsed in absolute ethanol, air dried, and counted for radioactivity. Inhibition of HBV DNA polymerase activity by PCV-TP was expressed as the percentage difference in activity in the assay mix containing PCV-TP compared to the matched control. Because of limited sample amounts, it was not possible to standardize enzyme activity or to perform replicate assays. Despite the inherent variability of the assay, a general time related decrease in sensitivity of the HBV DNA polymerase to PCV-TP was evident (see Table 1). - Upon commencement of the antiviral treatment strategy GCV+PFF, the level of HBV DNA post-OLT decreased from over 100,000 pg/ml to 10,800 pg/ml by day 87 (
FIG. 1 ). This reduction in viraemia was associated with clinical, biochemical and histological improvement (12). Maintenance famciclovir therapy (treatment GCV) resulted in fluctuating levels of HBV DNA over the ensuring 359 days with two peaks of HBV DNA observed. The switch to oral famciclovir onday 446 was also associated with a rise in HBV DNA, but this was likely to have been the result of insufficient dosing (FCV[I] inFIG. 2 ) rather than a breakthrough in treatment. Following dose increase to FCV [II] onday 500, there was a decrease in HBV DNA. However, the level of HBV DNA gradually rose over time from 3,000 pg/ml on day 600 (154 days of famciclovir), to 8,800 pg/ml on day 816 (370 days famciclovir), peaking at 29,000 pg/ml on day 1302 (856 days of famciclovir), then stabilising at around 12,000 pg/ml on day 1329 (883 days of famciclovir). A students test of the DNA levels during the treatment period fromdays 816 todays 1329, revealed statistically significant rise. There was a 1.5 to 2 fold rise in ALT levels over the same time interval (FIG. 2 ) and no change in clinical status. - The X and the polymerase genes of HBV were sequenced at five time points (
FIG. 2 ). During almost 4 years of the antiviral therapy there were no changes in the X gene compared to the pretreatment sequence. However, there were 5 nt changes detected in the polymerase gene fromday 816 andday 1329 samples (Table 1). These changes were detected in separate independent PCR amplifications; furthermore the mutations were detected by sequencing both strands and are therefore unlikely to be the result of PCR generated errors. The nt changes in the polymerase gene were first detected after 816 days of treatment, when the patient had been treated with famciclovir for 370 days. However, only two nt changes, at positions 1498 and 1519 resulted in amino acid changes, Val 519-Leu and Leu 526-Met, respectively. These two nt changes appeared concurrently. At 816 days, three different nt (C,G,T) were detected at position 1498 (all of which would result in a Val to Leu change). After 1329 days post-treatment, thymidine was the dominant species at nt 1498. The amino acid changes at 816 and 1329 days post treatment coincided with reduced serum HBV DNA polymerase sensitivity to PCV-TP (Table 1). These nt changes were not found in 6 patients with post-OLT recurrent HBV infection who were not undergoing FCV therapy. - The region encompassing the nt mutations which gave rise to amino acid changes from the sample taken at 1329 days was cloned and sequenced. Three quasi-species were detected. Seventy-five percent (15/20) of the clones contained both the 1498 and 1519 mutations which occurred together. Pretreatment non-mutated sequences were detected in 3/20 of the clones. A further mutation at nt 1511, which would result in a proline to leucine change at position 523, was detected in 2/20 of the clones. This mutation was not detected with the two dominant mutations, 1498 (Val 519-Leu) and 1519 (Leu 526-Met), nor was it detected by direct PCR sequencing, indicating it probably occurs at a low frequency. Viral DNA from the sample obtained at 600 days (150 days of FCV treatment) was also cloned and sequenced; however, only the pre-treatment sequences were detected.
- The amino acid changes in HBV isolated from patients B and C are shown in
FIG. 5 , and from patient D is shown inFIG. 6 . InFIG. 5 , patient A is the same as shown inFIG. 3 . - Patient B was undergoing long term famciclovir treatment (>850 days). The amino acid change selected during famciclovir treatment is shown as HBV (patient B) in
FIG. 5 . Patient C did not respond to famciclovir and was later treated with 3TC (lamivudine [6,7]). The HBV isolated during FCV treatment from patient C, is shown as HBV (patient C-FCV). All 3TC resistance mutations which developed during treatment with 3TC is shown as HBV (patient C-3TC). The sequence analysis showed a mutation (Thr-Ser substitution) in the HBV polymerase gene near the C domain but no mutation was initially detected in the YMDD motif A mutation ofMet 550 to Ile in the YMDD motif was detected from HBV isolated 32 days (333 days post treatment) after the HBV containing the Thr-Ser substitution was isolated. - Using the method hereinbefore described, HBV variants are screened for escape mutations. These are mutations in surface components such as the HBV surface antigen which reduce the interactivity of the surface component to antibodies or other immunological reagents. Given the overlapping open reading frame of HBV genome, a single mutation may have multiphenotypic consequences. For example, a mutation in the HBV DNA polymerase may also have an affect on the HBV surface antigen.
- Preferred mutations in the HBV surface antigen are in amino acids 118 to 169 and/or 169 to 207 such as D144E or G145R. These correspond to DNA polymerase mutations G498E and V499L.
- A particularly preferred escape mutant and nucleoside analogue resistant mutant has a nucleotide sequence set forth in
FIG. 6 with corresponding amino acid sequences for the DNA polymerase and surface antigen. - Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.
-
TABLE 1 Nucleotide mutations in the polymerase gene and the resulting amino acid changes during antiviral therapy Inhibition of Days of Days of HBV DNA antiviral famciclovir POLYMERASE GENE Polymerase by treatment treatment nt 297 nt 1498 nt1511* nt 1519 nt 2008 nt 2331 PCV-TP** Pretreatment NR*** T G C C C G 40% 87 NR — — — — — — NA**** 600 154 — — — — — — 30% 816 370 — G, T, C — A — — 0% 1329 883 C T T A A A 0% Amino acid change None Val 519-Leu Pro 523-Leu Leu 526-Met None None The dashes indicate no change from the pre-treatment nucleotide. *The mutation was only detected after cloning the PCR product after 1329 days of antiviral treatment. It occurred at a low frequency and was present in only 10% of clones. **The percentage inhibition of HBV DNA polymerase by PCV-TP in the in vitro assay as described in the Methods section. ***NR—not relevant ****NA—not assessable - 1. Summers J, Mason W. Cell (1982) 29: 403-415.
- 2. Vere Hodge R. A. Antiviral Chem Chemother (1993) 4:67-84.
- 3. Boyd M R et al Antiviral Chem Chemother. (1987) 32: 358-363.
- 4. Kruger T et al Hepatology (1994) 22: 219A.
- 5. Main J et al. J. Viral Hepatitis (1996) 3:211-215.
- 6. Severini A et al Antimicrobial Agents Chemother (1995) 39: 1430-1435.
- 7. Dienstag J L et al New England J Med (1995) 333: 1657-1661.
- 8. Shaw T, et al. Antimicrobiol Agents Chemother (1994) 38:719-723.
- 9. Shaw T, et al. Hepatology (1996) 24: in press.
- 10. Tsiquaye K N, et al. J. Med Virol (1994) 42: 306-310.
- 11. Boker K H W, et al. Transplantation (1994) 57: 1706-1708.
- 12. Angus P, et al. J. Gastroenterol Hepatol (1993) 8: 353-357.
- 13. Poch O, et al. EMBO J. (1989) 8: 3867-3874.
- 14. Delarue M, et al. Protein Engineering (1990) 3: 461-467.
- 15. Chiou H C, et al. Antiviral Chem Chemother (1995) 6: 281-288.
- 16. Ling R, et al. Hepatology (1996) 24: 711-713.
- 17. Price P M, et al. Hepatology 1992 16: 8-13.
Claims (17)
1. An isolated HBV mutant, comprising one or more mutations in the gene encoding the HBV polymerase resulting in decreased sensitivity to a nucleoside analogue compared to a wild-type HBV, wherein said mutation(s) result(s) in at least one amino acid addition, substitution and/or deletion in the A domain corresponding to amino acid residues 421-436 of a wild-type HBV polymerase and/or in the D domain corresponding to amino acid residues 576-588 of a wild-type HBV polymerase and/or in the E domain corresponding to amino acid residues 592-600 of a wild-type HBV polymerase, or in a region proximal thereto.
2. An isolated HBV mutant according to claim 1 , comprising one or more mutations in the gene encoding the HBV polymerase resulting in decreased sensitivity to a nucleoside analogue compared to a wild-type HBV, wherein said mutation(s) result(s) in at least one amino acid addition, substitution and/or deletion in the A domain corresponding to amino acid residues 421-436 of a wild-type HBV polymerase.
3. An isolated HBV mutant according to claim 1 , comprising one or more mutations in the gene encoding the HBV polymerase resulting in decreased sensitivity to a nucleoside analogue compared to a wild-type HBV, wherein said mutation(s) result(s) in at least one amino acid addition, substitution and/or deletion in the D domain corresponding to amino acid residues 576-588 of a wild-type HBV polymerase.
4. An isolated HBV mutant according to claim 1 , comprising one or more mutations in the gene encoding the HBV polymerase resulting in decreased sensitivity to a nucleoside analogue compared to a wild-type HBV, wherein said mutation(s) result(s) in at least one amino acid addition, substitution and/or deletion in the E domain corresponding to amino acid residues 592-600 of a wild-type HBV polymerase.
5. A method for determining the potential for an HBV to exhibit reduced sensitivity to a nucleoside analogue, said method comprising isolating DNA or corresponding mRNA from said HBV and screening for one or more mutation(s) in the nucleotide sequence encoding HBV DNA polymerase resulting in at least one amino acid substitution, deletion and/or addition in the D domain or E domain or a region proximal thereto of said DNA polymerase wherein the presence of such a mutation is an indication of the likelihood of resistance to said nucleoside analogue.
6. A method for determining whether an HBV isolate encodes a variant DNA polymerase, said method comprising determining the amino acid sequence of its DNA polymerase directly or via a nucleotide sequence and comparing same to the amino acid sequence below (SEQ ID NO:29):
where the presence of a different amino acid from the consensus sequence in the D or E domain indicates a putative HBV mutant.
7. The method according to one of claim 5 or claim 6 , wherein the screening for a mutation or determining the amino acid sequence comprises sequencing said isolated HBV DNA or corresponding DNA.
8. The method according to one of claim 5 or claim 6 , wherein the screening for a mutation or determining the amino acid sequence comprises a PCR method or PCR-based method.
9. The method according to one of claim 5 or claim 6 , wherein the screening for a mutation or determining the amino acid sequence comprises a hybridization method.
10. A method for determining whether an HBV isolate encodes a variant DNA polymerase said method comprising determining the amino acid sequence of the A domain (corresponding to amino acid residues 421-436) or a region proximal thereto (corresponding to amino acid residues 437-456) directly or via a nucleotide sequence and comparing same to the A domain or the region proximal thereto of the following amino acid sequence (SEQ ID NO:29):
11. A method for determining whether an HBV isolate encodes a variant DNA polymerase according to claim 10 said method comprising determining the amino acid sequence of the D domain (corresponding to amino acid residues 576-588) or a region proximal thereto directly or via a nucleotide sequence and comparing same to the D domain or the region proximal thereto of the following amino acid sequence (SEQ ID NO:29):
12. A method for determining whether an HBV isolate encodes a variant DNA polymerase according to claim 10 said method comprising determining the amino acid sequence of the E domain (corresponding to amino acid residues 592-600) or a region proximal thereto directly or via a nucleotide sequence and comparing same to the E domain or the region proximal thereto of the following amino acid sequence (SEQ ID NO:29)
13. The method according to claim 10 , wherein the determining comprises screening for a mutation comprises sequencing said isolated HBV DNA or corresponding DNA.
14. The method according to claim 10 , wherein the determining comprises screening for a mutation comprises a PCR method or PCR-based method.
15. The method according to claim 10 , wherein the determining comprises screening for a mutation comprises a hybridization method.
16. HBV isolate encoding a variant DNA polymerase as detected by the method of any one of the claims 10 -12.
17. A kit for assays for detecting a HBV isolate according to claim 16 comprising one or more reagents chosen from the group consisting of nucleic acid hybridisation technology as PCR and reagents for immunologically based detection techniques.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/547,392 US20130171620A1 (en) | 1996-11-08 | 2012-07-12 | Viral variants and methods for detecting same |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPO3519 | 1996-11-08 | ||
AUPO3519A AUPO351996A0 (en) | 1996-11-08 | 1996-11-08 | Viral variants and methods for detecting same |
PCT/AU1997/000520 WO1998021317A1 (en) | 1996-11-08 | 1997-08-15 | Viral variants and methods for detecting same |
US09/306,420 US6555311B1 (en) | 1996-11-08 | 1999-05-06 | Viral variants and methods for detecting same |
US10/260,451 US20030124096A1 (en) | 1996-11-08 | 2002-10-01 | Viral variants and methods for detecting same |
US12/117,869 US20100203506A1 (en) | 1996-11-08 | 2008-05-09 | Viral variants and methods for detecting same |
US13/547,392 US20130171620A1 (en) | 1996-11-08 | 2012-07-12 | Viral variants and methods for detecting same |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/117,869 Division US20100203506A1 (en) | 1996-11-08 | 2008-05-09 | Viral variants and methods for detecting same |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130171620A1 true US20130171620A1 (en) | 2013-07-04 |
Family
ID=3797830
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/306,420 Ceased US6555311B1 (en) | 1996-11-08 | 1999-05-06 | Viral variants and methods for detecting same |
US10/260,451 Abandoned US20030124096A1 (en) | 1996-11-08 | 2002-10-01 | Viral variants and methods for detecting same |
US12/117,869 Abandoned US20100203506A1 (en) | 1996-11-08 | 2008-05-09 | Viral variants and methods for detecting same |
US13/547,392 Abandoned US20130171620A1 (en) | 1996-11-08 | 2012-07-12 | Viral variants and methods for detecting same |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/306,420 Ceased US6555311B1 (en) | 1996-11-08 | 1999-05-06 | Viral variants and methods for detecting same |
US10/260,451 Abandoned US20030124096A1 (en) | 1996-11-08 | 2002-10-01 | Viral variants and methods for detecting same |
US12/117,869 Abandoned US20100203506A1 (en) | 1996-11-08 | 2008-05-09 | Viral variants and methods for detecting same |
Country Status (10)
Country | Link |
---|---|
US (4) | US6555311B1 (en) |
EP (1) | EP0964916B1 (en) |
JP (4) | JP2001503277A (en) |
AT (1) | ATE348880T1 (en) |
AU (1) | AUPO351996A0 (en) |
CA (1) | CA2270178C (en) |
DE (1) | DE69737126T2 (en) |
ES (1) | ES2279542T3 (en) |
HK (1) | HK1027374A1 (en) |
WO (1) | WO1998021317A1 (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA973367B (en) * | 1996-04-19 | 1997-11-18 | Innogenetics Nv | Method for typing and detecting HBV. |
USRE40233E1 (en) | 1996-11-08 | 2008-04-08 | Melbourne Health | Viral variants and methods for detecting same |
AUPO351996A0 (en) * | 1996-11-08 | 1996-12-05 | Western Health Care Network | Viral variants and methods for detecting same |
AUPP706098A0 (en) * | 1998-11-11 | 1998-12-03 | North Western Health Care Network | Biological compositions, components thereof and uses therefor |
AUPP967999A0 (en) * | 1999-04-09 | 1999-05-06 | North Western Health Care Network | Viral variants |
AR028149A1 (en) * | 1999-07-08 | 2003-04-30 | Innogenetics Nv | DETECTION OF RESISTANCE TO DRUGS AGAINST HEPATITIS B |
AUPQ810900A0 (en) | 2000-06-09 | 2000-07-06 | Austin and Repatriation Medical Centre, The | Viral variants and methods of using same |
SG90149A1 (en) * | 2000-07-18 | 2002-07-23 | Government Of The Republic Of | Diagnostic assay |
US6697858B1 (en) * | 2000-08-14 | 2004-02-24 | Telephony@Work | Call center |
EP2319917A3 (en) * | 2002-02-07 | 2012-02-08 | Melbourne Health | Viral variants with altered susceptibility to nucleoside analogs and uses thereof |
US7405039B2 (en) | 2002-02-07 | 2008-07-29 | Austin Health | Viral variants with altered susceptibility to nucleoside analogs and uses thereof |
US8278432B2 (en) | 2002-03-29 | 2012-10-02 | Innogenetics N.V. | HBV drug resistance methods |
WO2003087351A1 (en) | 2002-04-12 | 2003-10-23 | Melbourne Health | Hepatitis b viral variants with redused susceptibility to nucleoside analogs and uses thereof |
AU2003213874B2 (en) * | 2002-04-12 | 2008-12-04 | Austin Health | Hepatitis B viral variants with redused susceptibility to nucleoside analogs and uses thereof |
CA2486420C (en) | 2002-06-14 | 2014-04-15 | Gen-Probe Incorporated | Compositions and methods for detecting hepatitis b virus |
AU2003277208A1 (en) * | 2002-10-01 | 2004-04-23 | Georgetown University | Diagnostic for long term response of hbv carrier to 3tc therapy |
PL1858915T3 (en) | 2005-03-15 | 2015-01-30 | Univ Bonn Rheinische Friedrich Wilhelms | Variants of hepatitis b virus resistant against some nucleoside analogues, but sensitive to others, and uses thereof |
JP2008537483A (en) | 2005-03-15 | 2008-09-18 | イノジェネティックス・ナムローゼ・フェンノートシャップ | Hepatitis B virus variants with reduced sensitivity to nucleoside analogues and uses thereof |
US8211443B2 (en) | 2005-04-08 | 2012-07-03 | Melbourne Health | Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof |
JP2008534020A (en) | 2005-04-08 | 2008-08-28 | メルボルン ヘルス | Hepatitis B virus variant resistant to antiviral nucleoside agents and application method thereof |
KR100790226B1 (en) | 2005-11-03 | 2008-01-02 | 연세대학교 산학협력단 | Method for determining the susceptibility to toxic hepatitis |
US9175341B2 (en) * | 2008-12-11 | 2015-11-03 | Pacific Biosciences Of California, Inc. | Methods for identifying nucleic acid modifications |
US9175338B2 (en) | 2008-12-11 | 2015-11-03 | Pacific Biosciences Of California, Inc. | Methods for identifying nucleic acid modifications |
US20230148447A9 (en) | 2008-12-11 | 2023-05-11 | Pacific Biosciences Of California, Inc. | Classification of nucleic acid templates |
EP2694686B2 (en) | 2011-04-06 | 2023-07-19 | The University of Chicago | COMPOSITION AND METHODS RELATED TO MODIFICATION OF 5-METHYLCYTOSINE (5mC) |
US9238836B2 (en) | 2012-03-30 | 2016-01-19 | Pacific Biosciences Of California, Inc. | Methods and compositions for sequencing modified nucleic acids |
US9175348B2 (en) | 2012-04-24 | 2015-11-03 | Pacific Biosciences Of California, Inc. | Identification of 5-methyl-C in nucleic acid templates |
CN115003685A (en) * | 2019-12-07 | 2022-09-02 | Isa制药有限公司 | Treatment of hepatitis B virus related diseases |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5595739A (en) * | 1993-05-07 | 1997-01-21 | Abbott Laboratories | Hepatitis B virus mutants, reagents and methods for detection |
ZA973367B (en) * | 1996-04-19 | 1997-11-18 | Innogenetics Nv | Method for typing and detecting HBV. |
USRE40233E1 (en) * | 1996-11-08 | 2008-04-08 | Melbourne Health | Viral variants and methods for detecting same |
AUPO351996A0 (en) * | 1996-11-08 | 1996-12-05 | Western Health Care Network | Viral variants and methods for detecting same |
AUPP967999A0 (en) * | 1999-04-09 | 1999-05-06 | North Western Health Care Network | Viral variants |
AUPQ810900A0 (en) * | 2000-06-09 | 2000-07-06 | Austin and Repatriation Medical Centre, The | Viral variants and methods of using same |
US7405039B2 (en) * | 2002-02-07 | 2008-07-29 | Austin Health | Viral variants with altered susceptibility to nucleoside analogs and uses thereof |
US8278432B2 (en) * | 2002-03-29 | 2012-10-02 | Innogenetics N.V. | HBV drug resistance methods |
WO2003087351A1 (en) * | 2002-04-12 | 2003-10-23 | Melbourne Health | Hepatitis b viral variants with redused susceptibility to nucleoside analogs and uses thereof |
WO2005042733A1 (en) * | 2003-10-21 | 2005-05-12 | Melbourne Health | Hbv variants detection and application |
PL1858915T3 (en) * | 2005-03-15 | 2015-01-30 | Univ Bonn Rheinische Friedrich Wilhelms | Variants of hepatitis b virus resistant against some nucleoside analogues, but sensitive to others, and uses thereof |
JP2008537483A (en) * | 2005-03-15 | 2008-09-18 | イノジェネティックス・ナムローゼ・フェンノートシャップ | Hepatitis B virus variants with reduced sensitivity to nucleoside analogues and uses thereof |
US8211443B2 (en) * | 2005-04-08 | 2012-07-03 | Melbourne Health | Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof |
JP2008534020A (en) * | 2005-04-08 | 2008-08-28 | メルボルン ヘルス | Hepatitis B virus variant resistant to antiviral nucleoside agents and application method thereof |
US8859198B2 (en) * | 2006-06-06 | 2014-10-14 | Abl Sa | Detection and use of antiviral resistance mutations |
-
1996
- 1996-11-08 AU AUPO3519A patent/AUPO351996A0/en not_active Abandoned
-
1997
- 1997-08-15 DE DE69737126T patent/DE69737126T2/en not_active Expired - Lifetime
- 1997-08-15 EP EP97934385A patent/EP0964916B1/en not_active Expired - Lifetime
- 1997-08-15 JP JP52194498A patent/JP2001503277A/en not_active Withdrawn
- 1997-08-15 AT AT97934385T patent/ATE348880T1/en active
- 1997-08-15 ES ES97934385T patent/ES2279542T3/en not_active Expired - Lifetime
- 1997-08-15 CA CA2270178A patent/CA2270178C/en not_active Expired - Lifetime
- 1997-08-15 WO PCT/AU1997/000520 patent/WO1998021317A1/en active IP Right Grant
-
1999
- 1999-05-06 US US09/306,420 patent/US6555311B1/en not_active Ceased
-
2000
- 2000-06-22 HK HK00103809A patent/HK1027374A1/en not_active IP Right Cessation
-
2002
- 2002-10-01 US US10/260,451 patent/US20030124096A1/en not_active Abandoned
-
2008
- 2008-01-24 JP JP2008014075A patent/JP2008154590A/en active Pending
- 2008-05-09 US US12/117,869 patent/US20100203506A1/en not_active Abandoned
-
2011
- 2011-12-16 JP JP2011276121A patent/JP2012055322A/en active Pending
-
2012
- 2012-07-12 US US13/547,392 patent/US20130171620A1/en not_active Abandoned
-
2015
- 2015-02-02 JP JP2015018686A patent/JP2015107127A/en active Pending
Non-Patent Citations (1)
Title |
---|
Khrapko et al. An oligonucleotide hybridization approach to DNA sequencing. Federation of European Biochemical Societies, 1989, Vol. 256, p118-122. * |
Also Published As
Publication number | Publication date |
---|---|
AUPO351996A0 (en) | 1996-12-05 |
DE69737126T2 (en) | 2007-10-04 |
EP0964916A1 (en) | 1999-12-22 |
DE69737126D1 (en) | 2007-02-01 |
JP2012055322A (en) | 2012-03-22 |
US6555311B1 (en) | 2003-04-29 |
CA2270178A1 (en) | 1998-05-22 |
JP2008154590A (en) | 2008-07-10 |
ES2279542T3 (en) | 2007-08-16 |
US20030124096A1 (en) | 2003-07-03 |
CA2270178C (en) | 2012-06-12 |
US20100203506A1 (en) | 2010-08-12 |
WO1998021317A1 (en) | 1998-05-22 |
EP0964916B1 (en) | 2006-12-20 |
JP2001503277A (en) | 2001-03-13 |
EP0964916A4 (en) | 2001-09-26 |
ATE348880T1 (en) | 2007-01-15 |
JP2015107127A (en) | 2015-06-11 |
HK1027374A1 (en) | 2001-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20130171620A1 (en) | Viral variants and methods for detecting same | |
Tillmann et al. | Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation | |
US7931907B2 (en) | Hepatitis B virus DNA polymerase and surface antigen variants and methods of using same | |
Sterneck et al. | Hepatitis B virus genomes of patients with fulminant hepatitis do not share a specific mutation | |
CN101203528A (en) | Hepatitis-b viral variants with reduced susceptibility to nucleoside analogs and uses thereof | |
KR100370341B1 (en) | Hepatitis B Vaccine | |
JPH08503846A (en) | Hepadnavirus polymerase gene product having RNA-dependent DNA priming and reverse transcriptase activity and method for measuring the activity | |
AU734831B2 (en) | Viral variants and methods for detecting same | |
AU656136B2 (en) | Methods of preventing viral replication | |
Pardoe et al. | Detection of hepatitis B and woodchuck hepatitis viral DNA in plasma and mononuclear cells from heparinized blood by the polymerase chain reaction | |
USRE40233E1 (en) | Viral variants and methods for detecting same | |
Karasawa et al. | Association between frequency of amino acid changes in core region of hepatitis B virus (HBV) and the presence of precore mutation in Japanese HBV carriers | |
Kuwahara et al. | Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy | |
Robinson et al. | The hepadna viruses of animals | |
AU780978B2 (en) | Viral variants and methods for detecting same | |
Lee et al. | Overlapping gene mutations of hepatitis B virus in a chronic hepatitis B patient with hepatitis B surface antigen loss during lamivudine therapy | |
AU2001263672B2 (en) | Hepatitis B virus DNA polymerase and surface antigen variants and methods of using same | |
Nguyen et al. | Precore region mutation in hepatitis B virus genome in early stage of infection: a study in hepatitis B e antigen-positive young carriers | |
AU2001263672A1 (en) | Hepatitis B virus DNA polymerase and surface antigen variants and methods of using same | |
Non-Occult | Bioscience Research | |
Yuan | Characterization of naturally occurring mutations in the precore and core genes of hepatitis B virus | |
MXPA01003205A (en) | An in vitro |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ABL SA, LUXEMBOURG Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:EVIVAR MEDICAL PTY LTD.;REEL/FRAME:030694/0918 Effective date: 20130617 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: EVIVAR MEDICAL PTY LTD., AUSTRALIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MELBOURNE HEALTH;SOUTHERN HEALTH;ST VINCENT'S HOSPITAL (MELBOURNE) LIMITED;AND OTHERS;SIGNING DATES FROM 20130617 TO 20140617;REEL/FRAME:033489/0883 |